

## THE CONSORTIUM



## FUNDERS



This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820755. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV, Accelerate Diagnostics S.L., Abbott, Bio-Rad Laboratories, BD Switzerland Sàrl, and The Wellcome Trust Limited.

## CONTACT

David De Pooter

VALUE-Dx Project Manager

David.DePooter@uantwerpen.be

## ABOUT VALUE-Dx

VALUE-Dx is the first Innovative Medicines Initiative project initiated by 6 in vitro diagnostic companies who joined forces with 20 non-industry partners to combat antimicrobial resistance (AMR) and improve patient outcomes. Unique in its multidisciplinary nature, it involves clinicians, microbiologists, health economists, social scientists, and industry jointly to help build the medical and economic case for rapid diagnostics as a public good in the fight against antimicrobial resistance.

## OBJECTIVES



To design a **health-economic framework** to assess and demonstrate the value of diagnostics both for individual patients and for public health by reducing antibiotic use and subsequent AMR among patients.



To establish a **sustainable European Standardised Care Network** adequately trained and resourced to conduct clinical trials evaluating the value of diagnostics.



To design and implement **clinical studies** to demonstrate the value of diagnostics in the optimal management of Community Acquired-Respiratory Tract Infections (CA-ARTIs).



To explore, define and **attempt to resolve the psychological, ethical and social barriers** which prevent the more widespread adoption of diagnostics delivering healthcare to the population.

## POINT PREVALENCE AUDIT SURVEY (PPAS)

PPAS is a study that aims **to record information about patients who seek healthcare for CA-ARTIs**. Researchers will collect information from a range of healthcare settings where antibiotics are prescribed for patients who have respiratory infections, including general practice, urgent care centres, accident and emergency, and other acute services in hospitals, paediatric care centres, and long-term care facilities. This will help researchers benchmark patterns of testing and antibiotic prescribing in contrasting European settings by observing current practices in routine care.

## PRUDENCE AND ADEQUATE STUDIES

**PRUDENCE** (*Platform randomised controlled trial of point-of-care diagnostics for enhancing the quality of antibiotic prescribing for community acquired-acute respiratory tract infections (CA-ARTIs) in community care in Europe*) is a pragmatic and flexible platform clinical trial to evaluate the clinical- and cost-effectiveness of CA-ARTI diagnostics to safely reduce antibiotic use in community care settings. **ADEQUATE** is a randomised controlled trial to evaluate rapid syndromic diagnostic testing for enhancing the quality of antibiotic prescribing for CA-ARTI in emergency rooms in Europe.

The **PRUDENCE** and **ADEQUATE** trials will evaluate clinical algorithms that incorporate diagnostic point-of-care tests. The clinical- and cost-effectiveness of

- ▶ algorithms that incorporate a point-of-care test will be compared to outcomes from management that does not include point of care testing. **The goal of the overall programme is to better target antibiotic prescribing in order to combat antimicrobial resistance.**



## CURRENTLY AVAILABLE ANTIBIOTICS MUST BE USED WISELY TO PRESERVE EFFECTIVENESS

**CA-ARTIs are:**

**the most frequent acute disease** for consulting community health care

**the most common syndrome** for which unnecessary antibiotics are prescribed

**VALUE-Dx** is focusing its research on diagnostic strategies relevant to reduce AMR in CA-ARTIs in community care settings (Primary Care, Emergency Departments of Hospitals), which are the main first points of contact with health services.